CDEK
← All organizations

Incyte

For profitContributed to NMEWebsite ↗

Also known as: Incyte Biosciences International Sàrl | Incyte Biosciences Japan GK | Incyte Biosciences UK | Incyte Biosciences UK Ltd | Incyte Corp. | INCYTE CORP | Incyte Corporation | Incyte Pharmaceuticals

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2005

First marketed drug

Nov 16, 2011

First NDA

Nov 16, 2011

Last known activity

May 1, 2026

Timeline

1990s

  1. Jan 1, 1991

    Incyte— Founded

  2. Jan 1, 1997

    Synteni— Acquired

2000s

  1. Jan 1, 2001

    Proteome— Acquired

  2. Feb 18, 2003

    Maxia Pharmaceuticals— Acquired

2020s

  1. Apr 17, 2020

    pemigatinib— NDA Organization

  2. Apr 17, 2020

    pemigatinib— Marketing Organization

  3. Apr 17, 2020

    pemigatinib— NDA Secondary Org

  4. Apr 23, 2024

    Escient Pharmaceuticals, Inc— Acquired

Drugs by trial phase (192 distinct, 452 trials)

Phase 4 (2 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (4)

Subsidiaries (4 direct, 4 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Palo Alto, CA, US Jan 1, 1991
First NDA
Nov 16, 2011
Last known activity
May 1, 2026

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy
  • Accelerated approval